



AROV I® Enoxaparin
made in Europe

AROV I® and ROVI Biotech Ltd

The European Specialist in Heparins

November 2018



Disclaimer

This document has been prepared by Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”), solely for its use during the attached presentation.

The information and each of the opinions and statements contained in this document have not been verified by independent experts and, therefore, no guarantee is provided of the impartiality, accuracy, completeness or precision of the information or opinions and statements contained in this presentation.

The Company and its advisors do not assume responsibility for any damage or losses that may arise from the use of this document or the information it contains.

This document does not constitute an offer or invitation to acquire or subscribe shares, in accordance with the Spanish Securities Market Law of 1988 and its implementing regulations. Moreover, this document does not constitute an offer to purchase, sell or exchange securities, a solicitation of any offer to purchase, sell or exchange securities, a solicitation of any kind of voting rights, or approval in the United States of America or any other jurisdiction.

Neither this document nor any part of it are of a contractual nature, and they cannot be used to form part or construe any agreement or any kind of undertaking.

This presentation may contain information and statements or declarations with future projections regarding ROVI. The future projections do not constitute historical facts and are generally identifiable by the use of terms such as “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions.

In this regard, although ROVI believes that the expectations contained in such statements are reasonable, the investors and holders of ROVI shares are advised that the information and future projections are subject to risks and uncertainties, a large part of which are difficult to foresee, and which are, in general, out of ROVI's control. These risks could cause the results and real development to differ substantially from those expressed, implicit or projected, in the information and future projections. Among these risks and uncertainties include those identified in the documents submitted by ROVI to the Spanish Securities Exchange Commission (*Comisión Nacional del Mercado de Valores*), which are available to the public.

It is recommended that investment decisions not be taken based on the future projections, which refer exclusively to the date on which they were publicised. All the future projections contained below and made by ROVI or any of its directors, managers, employees or representatives are expressly subject to the above warnings. The future projections included in this presentation are based on the information available on the date hereof. Except when legally required, ROVI does not assume any obligation to update its affirmations or review the future projections, even if new data is published or new facts arise.





AROVI[®] Enoxaparin
made in Europe

Product Range




The European specialist in heparins

AROVI®: The same dosage, indications and method of administration as the reference medicine

AROVI® Strengths	Pack Sizes	Product License Number	PIP Code	EAN13 - CODE
2,000 IU (20 mg)/0.2 mL	10 Syringes	PL 15406/0007	408-0867	8437009577-912
4,000 IU (40 mg)/0.4 mL	10 Syringes	PL 15406/0008	408-0859	8437009577-929
6,000 IU (60 mg)/0.6 mL	10 Syringes	PL 15406/0009	408-0875	8437009577-936
8,000 IU (80 mg)/0.8 mL	10 Syringes	PL 15406/0010	408-0883	8437009577-943
10,000 IU (100 mg)/1 mL	10 Syringes	PL 15406/0002	408-0891	8437009577-950
12,000 IU (120 mg)/0.8 mL	10 Syringes	PL 15406/0006	406-1263	8437009577-899
15,000 IU (150 mg)/1 mL	10 Syringes	PL 15406/0003	406-1214	8437009577-905




Product Range (box) - AROVI®




AROVI® 20mg/0.2ml
Pack of 10 PFS



AROVI® 40mg/0.4ml
Pack of 10 PFS



AROVI® 60mg/0.6ml
Pack of 10 PFS



AROVI® 80mg/0.8ml
Pack of 10 PFS



AROVI® 100mg/1ml
Pack of 10 PFS



AROVI® 120mg/0.8ml
Pack of 10 PFS



AROVI® 150mg/1ml
Pack of 10 PFS

- Each PACK is color coded with a different color to avoid prescription and dispensing errors.





AROVI® **20mg/0.2ml**
Pack of 10 PFS



AROVI® **40mg/0.4ml**
Pack of 10 PFS



AROVI® **60mg/0.6ml**
Pack of 10 PFS



AROVI® **80mg/0.8ml**
Pack of 10 PFS



AROVI® **100mg/1ml**
Pack of 10 PFS



AROVI® **120mg/0.8ml**
Pack of 10 PFS



AROVI® **150mg/1ml**
Pack of 10 PFS

- Each LABEL is color coded with a different color to avoid prescription and dispensing errors (example of PFS with activated device).






AROVI[®] Enoxaparin
made in Europe


Safety Device



The European specialist in heparins

- AROVI® includes the safety device **Preventis™** from **Becton Dickinson**
- Preventis™ is an **automatic** needle **shielding system**. It has a cover or sleeve that **extends over** the needle following injection.
- After the injection, further pressure on the plunger activates the spring causing the needle shield to automatically **lock into place**.






1 AROVI® 40mg **before** the injection

2 AROVI® 40mg **after** the injection with the needle shield locked into place.

AROVI® safety device is an "active" device versus other devices called "passive".

The difference is that with an **active device** the patient controls the activation of the safety system.

- 1 After the injection, **further pressure** on the plunger rod activates the spring causing the needle shield to automatically lock into place.
- 2 The protective sleeve will automatically cover the needle producing an **audible click**.





AROVI[®] Enoxaparin
made in Europe

Educational Materials



The European specialist in heparins


1

**A3 poster
(for the wards)**




2

**A5 booklet
(for patients)**




3

Video



Available under request “free of cost”





- Matt
- Laminated

← 29.7cm →



How should I inject AROVI®?

AROVI® Administration VIDEO
To watch this video scan the QR code or visit <https://www.aroivi.com/aroivi-enoxaparin>

If you are able to give AROVI® to yourself, your doctor or nurse will show you how to do this. Do not try to inject yourself if you have not been trained how to do so. If you are not sure what to do, talk to your doctor or nurse immediately. Please refer to the package insert before use of the product.

Follow these steps BEFORE the injection

- 1** First wash your hands with soap and water and dry them carefully.
- 2** Administration is done in a comfortable position. The injection is recommended in the area of the abdominal fat tissue, more than 5 centimeters from the navel. DO NOT inject in an irritated site, near a mole or scar. Select the injection site alternately on the left and right sides.
- 3** Cleanse the selected area with a skin antiseptic disinfectant before the injection.

AROVI® pre-filled syringe is now ready to be used

The subcutaneous injection technique

- 4** Remove the syringe from the individual packaging and remove the cap by pulling firmly. The air must not be removed from the syringe. If a drop appears at the end of the needle, it should be removed by shaking. The needle is sterile, do not wipe it or touch it before use.
- 5** Make a skin fold in the abdominal area with forefinger and thumb. The skin fold must be maintained during the injection.
- 6** The entire length of the needle should be inserted VERTICALLY with a 90-degree angle into the skin fold. Slowly inject the contents by pushing the plunger towards the cylinder and maintaining the skin fold until the needle is removed at the end of the injection.
- 7** Remove the syringe while keeping your thumb on the plunger. To prevent bleeding, do not rub or scratch the puncture site after injection.
- 8** Check the syringe has been removed from the skin fold, press firmly on the plunger to activate the safety system. The protective cover engulfs the needle with an audible CLICK that confirms the activation of the safety system.

Immediately the syringe must be discarded by threading it into the nearest sharps bin. The cartridge must be closed tightly and kept out of the reach of children. To prevent bruising DO NOT rub the injection site after administration.

42 cm

AROVI® is available in a range of strengths:



- AROVI® 2000 IU (20 mg) x 100
- AROVI® 3000 IU (30 mg) x 100
- AROVI® 4000 IU (40 mg) x 100
- AROVI® 5000 IU (50 mg) x 100
- AROVI® 10000 IU (100 mg) x 100
- AROVI® 15000 IU (150 mg) x 100

What does AROVI® look like?


AROVI® is a clear, colorless to pale yellow solution in a pre-filled syringe fitted with an injection needle with a safety device. The pre-filled syringes are stored in plastic trays and carton boxes.



Reporting side effects: If you suffer any side effects talk to your doctor, pharmacist or nurse or call the NHS. This includes any side effects not listed in the package insert. You can also report side effects directly via the Yellow Card Scheme at <http://www.medicines.gov.uk/adr-uk>. Adverse events should be reported to MHRA (UK) at MHRA@medicines.gov.uk or by telephone 020 2054 2020. For more information on the safety of our medicines visit www.aroivi.com



2 – A5 BOOKLET – User Information Guide - AROVI®




14.8 x 21cm

Stapled Booklet

8 pages



3 – VIDEO – How to Inject - AROVI®



2 minutes

Public Access

<https://rovi.es/en/biosimilar-de-enoxaparina>

AROVI® Administration VIDEO

6



AROVI® Enoxaparin
made in Europe



The European specialist in heparins



AROVI[®] Enoxaparin
made in Europe

Bioequivalence Study



The European specialist in heparins

Drug Design, Development and Therapy

Dovepress

open access to scientific and medical research

Open Access Full Text Article

ORIGINAL RESEARCH

Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy

Javier Martínez González
Mayte Monreal
Ignacio Ayani Almagia
Jordi Llaudó Garín
Lourdes Ochoa Díaz de
Monasterioguren
Ibón Gutierrez Adúriz

R&D Department, Laboratorios
Farmacéuticos Rovi S.A., Madrid, Spain

Purpose: To demonstrate the pharmacokinetic/pharmacodynamic (PK/PD) equivalence of a biosimilar enoxaparin to the reference drug, and to assess its safety and tolerability in healthy volunteers.

Patients and methods: A randomized, double-blind, crossover, 2-sequence, single-dose study was conducted in healthy volunteers of both sexes. Participants were sequentially and randomly administered single subcutaneous injections of enoxaparin 100 mg manufactured by Rovi (test; Madrid, Spain) and Clexane® (enoxaparin 100 mg manufactured by Sanofi, reference) separated by a 1-week washout period. The primary PK/PD variables were maximum activity (A_{max}) and area under the effect curve from time 0 to the last measured activity (T) ($AUEC_{0-T}$) and $AUEC$ from time 0 to infinity ($AUEC_{0-inf}$) of anti-FXa activity, and A_{max} and $AUEC_{0-T}$ of anti-FIIa activity. Secondary variables were A_{max} and $AUEC_{0-T}$, $AUEC_{0-inf}$ of tissue factor pathway inhibitor, and the ratio of $AUEC_{0-T}$ anti-FXa to anti-FIIa activity. Biosimilarity would be shown when the 95% CI of the ratio of geometric least squares means (95% CI RGLSMs) of primary PK/PD parameters fell within the standard range of bioequivalence, ie, 80%–125%.

Results: The study sample consisted of 46 volunteers (33 males) aged 18–44 years and with body mass index ranging from 19.0 to 31.1 kg/m². Three subjects did not complete the study. The curves of anti-FXa, anti-FIIa and tissue factor pathway inhibitor activities corresponding to administration of the test and reference products were comparable. The 95% CI RGLSMs of A_{max} , $AUEC_{0-T}$ and $AUEC_{0-inf}$ for anti-FXa activity were 94.6%–105.9%, 99.8%–108.0% and

AROVI® is biosimilar to the innovator Clexane®

Available here:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865560/pdf/dddt-12-575.pdf>



The European specialist in heparins



AROVI[®] Enoxaparin
made in Europe

ROVI Biotech Limited

Davis House, 4th Floor, Robert Street
CR0 1QQ Croydon
Tel.: +44 (0) 203 642 06 77

inforovibiotechUK@rovi.com
UK-medicalinformation@rovi.com

www.rovi.com/en



The European specialist in heparins